目的 探討糖脈康顆粒聯(lián)合西格列汀治療2型糖尿病的臨床療效。方法 選取2022年7月—2024年7月南京醫(yī)科大學(xué)附屬江寧醫(yī)院內(nèi)分泌門診收治的110例2型糖尿病患者，根據(jù)隨機(jī)數(shù)字表法將所有患者分為對照組和治療組，每組各55例。對照組口服磷酸西格列汀片，100 mg/次，1次/d。治療組在對照組基礎(chǔ)上口服糖脈康顆粒，1袋/次，3次/d。兩組連續(xù)治療30 d。觀察兩組的臨床療效和癥狀好轉(zhuǎn)時(shí)間，比較兩組治療前后血糖指標(biāo)和血清炎性因子水平的變化情況。結(jié)果 治療后，治療組總有效率是96.36%，顯著高于對照組的83.64%(P<0.05)。治療后，治療組多飲、多食、多尿、乏力好轉(zhuǎn)時(shí)間均顯著短于對照組（P<0.05）。治療后，兩組患者空腹血糖（FPG）、糖化血紅蛋白（HbA1c）、2 h血糖（2 h PG）水平均顯著降低（P<0.05）；治療后，治療組FPG、HbA1c、2 h PG水平顯著低于對照組（P<0.05）。治療后，兩組患者血清白細(xì)胞介素-1β(IL-1β)、高遷移率族蛋白B1(HMGB1)、白細(xì)胞介素-6(IL-6)、血清單核細(xì)胞趨化蛋白-1(MCP-1)水平均顯著降低（P<0.05）；治療后，治療組IL-1β、HMGB1、IL-6、MCP-1水平低于對照組（P<0.05）。結(jié)論 與單獨(dú)使用西格列汀相比，糖脈康顆粒聯(lián)合西格列汀治療2型糖尿病具有較好的臨床療效，能降低患者血糖水平，縮短臨床癥狀好轉(zhuǎn)時(shí)間，并可降低血清炎性指標(biāo)，值得借鑒與應(yīng)用。

Objective To explore the clinical study of Tangmaikang Granule combined with sitagliptin in treatment of type 2 diabetes. Methods A total of 110 patients with type 2 diabetes admitted to the Endocrinology Clinic of Jiangning Hospital Affiliated to Nanjing Medical University from July 2022 to July 2024 were selected and divided into control group and treatment group according to random number table method,with 55 patients in each group.Patients in control group were po administered with Sitagliptin Phosphate Tablets,100 mg/time,once daily.Patients in treatment group were po administered with Tangmaikang Granule on the basis of control group,1bag/time,3 times daily.Both groups were treated continuously for 30 d.The clinical efficacy and symptom improvement time of two groups were observed,and the changes of blood glucose indexes and serum inflammatory factors before and after treatment were compared between the two groups. Results After treatment,the total effective rate of the treatment group was 96.36%,which was significantly higher than that of control group （83.64%,i>P＜0.05）.After treatment,the improvement time of polydipsia,polyphagia,polyuria,and fatigue in treatment group was significantly shorter than that in control group （i>P＜0.05）.After treatment,the levels of fasting blood glucose （FPG）,glycosylated hemoglobin （HbA1c）,and 2 h blood glucose （2 h PG） in two groups were significantly decreased （i>P＜0.05）.After treatment,the levels of FPG,HbA1c and 2 h PG in treatment group were significantly lower than those in control group （i>P＜0.05）.After treatment,the levels of serum interleukin-1β （IL-1β）,high mobility group protein B1 （HMGB1）,interleukin-6 （IL-6）,and serum monocyte chemotactic protein-1 （MCP-1） in two groups were significantly decreased （i>P＜0.05）.After treatment,the levels of IL-1β,HMGB1,IL-6,and MCP-1 in treatment group were lower than those in control group （P＜0.05）. Conclusion Compared to oral sitagliptin alone,Tangmaikang Granules combined with sitagliptin has a good clinical effect in treatment of type 2 diabetes,could reduce the blood glucose level,shorten the time of clinical symptom improvement,and decrease serum inflammatory index,which is worth learning and application.

R977

江蘇省衛(wèi)生健康委老年健康科研項(xiàng)目(LK2021061); 南京市衛(wèi)生科技發(fā)展項(xiàng)目(YKK23229)